Carboplatin dosing based on measurement of renal function - Experience at the Peter MacCallum Cancer Institute

被引:48
作者
Millward, MJ [1 ]
Webster, LK [1 ]
Toner, GC [1 ]
Bishop, JF [1 ]
Rischin, D [1 ]
Stokes, KH [1 ]
Johnston, VK [1 ]
Hicks, R [1 ]
机构
[1] PETER MACCALLUM CANC INST,DIV HAEMATOL & MED ONCOL,MELBOURNE,VIC 3000,AUSTRALIA
来源
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE | 1996年 / 26卷 / 03期
关键词
carboplatin; renal function; cancer; Peter MacCallum Cancer Institute;
D O I
10.1111/j.1445-5994.1996.tb01925.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Carboplatin is used in treating many types of cancer. Because renal excretion is the major variable determining the pharmacokinetics of this drug, a dosing formula based on glomerular filtration rate (GFR) has been proposed and is being increasingly used in carboplatin dosing. This method of dosing is critically dependent on accurate measurement of GFR. Aims: To report the experience at a single major oncology centre of carboplatin dosing based on GFR, and comparisons of different methods of measuring renal function for use in this dosing method. Methods: An initial group of patients (n=24) was studied where GFR was measured by Cr(51)EDTA clearance and compared to Tc(99m)DTPA clearance, measured 24 hour urine creatinine clearance and the Cockcroft and Gault formula. The carboplatin area under the plasma concentration versus time curve (AUC) was calculated using total platinum measured in a single blood sample assayed by flameless atomic absorption spectrophotometry. A subsequent patient group (n = 16) was then studied using Tc(99m)DTPA clearance to measure GFR. Results: Carboplatin dosing using Cr(51)EDTA clearance to measure GFR was accurate (<25% difference between planned and measured AUC) in 87% of samples. Estimation of renal function using the Cockcroft and Gault formula correlated with Cr(51)EDTA clearance only in patients with GFR <100 mL/minute. The measured 24 hour urine creatinine clearance did not correlate with Cr(51)EDTA clearance. Using Tc(99m)DTPA clearance to measure GFR, carboplatin dosing was accurate in 81% of samples. Across a GFR range of 42-239 mL/minute, the Cr(51)EDTA and Tc(99m)DTPA clearances were closely correlated (r = 0.98, slope of regression line = 1.02). Conclusions: Carboplatin dosing using a pharmacological formula based on GFR produces accurate targeting of the carboplatin AUC. Tc(99m)DTPA clearance can be used to measure GFR instead of Cr(51)EDTA clearance, which is both more convenient and has potential cost savings. Estimates of renal function using the Cockcroft and Gault formula or measured 24 hour creatinine clearance are insufficiently accurate to use for carboplatin dosing.
引用
收藏
页码:372 / 379
页数:8
相关论文
共 29 条
[1]   IMPROVED THERAPEUTIC INDEX OF CARBOPLATIN PLUS CYCLOPHOSPHAMIDE VERSUS CISPLATIN PLUS CYCLOPHOSPHAMIDE - FINAL REPORT BY THE SOUTHWEST-ONCOLOGY-GROUP OF A PHASE-III RANDOMIZED TRIAL IN STAGE-III AND STAGE-IV OVARIAN-CANCER [J].
ALBERTS, DS ;
GREEN, S ;
HANNIGAN, EV ;
OTOOLE, R ;
STOCKNOVACK, D ;
ANDERSON, P ;
SURWIT, EA ;
MALVLYA, VK ;
NAHHAS, WA ;
JOLLES, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :706-717
[2]   CARBOPLATIN (CBDCA, JM-8) AND VP-16-213 IN PREVIOUSLY UNTREATED PATIENTS WITH SMALL-CELL LUNG-CANCER [J].
BISHOP, JF ;
RAGHAVAN, D ;
STUARTHARRIS, R ;
MORSTYN, G ;
ARONEY, R ;
KEFFORD, R ;
YUEN, K ;
LEE, J ;
GIANOUTSOS, P ;
OLVER, IN ;
ZALCBERG, J ;
BALL, D ;
BULL, C ;
FOX, R .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) :1574-1578
[3]   SELECTION OF ROUTINE METHOD FOR DETERMINATION OF GLOMERULAR-FILTRATION RATE IN ADULT PATIENTS [J].
BROCHNERMORTENSEN, J ;
RODBRO, P .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1976, 36 (01) :35-43
[4]   IOHEXOL TO MONITOR GFR [J].
BROWN, S .
LANCET, 1992, 339 (8788) :306-307
[5]   EARLY CLINICAL-STUDIES WITH CIS-DIAMMINE-1,1-CYCLOBUTANE DICARBOXYLATE PLATINUM-II [J].
CALVERT, AH ;
HARLAND, SJ ;
NEWELL, DR ;
SIDDIK, ZH ;
JONES, AC ;
MCELWAIN, TJ ;
RAJU, S ;
WILTSHAW, E ;
SMITH, IE ;
BAKER, JM ;
PECKHAM, MJ ;
HARRAP, KR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (03) :140-147
[6]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[7]   CARBOPLATIN - CURRENT STATUS AND FUTURE-PROSPECTS [J].
CANETTA, R ;
BRAGMAN, K ;
SMALDONE, L ;
ROZENCWEIG, M .
CANCER TREATMENT REVIEWS, 1988, 15 :17-32
[8]   PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS [J].
CHATELUT, E ;
CANAL, P ;
BRUNNER, V ;
CHEVREAU, C ;
PUJOL, A ;
BONEU, A ;
ROCHE, H ;
HOUIN, G ;
BUGAT, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (08) :573-580
[9]   THE OPTIMIZATION OF CARBOPLATIN DOSE IN CARBOPLATIN, ETOPOSIDE AND BLEOMYCIN COMBINATION CHEMOTHERAPY FOR GOOD PROGNOSIS METASTATIC NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS [J].
CHILDS, WJ ;
NICHOLLS, EJ ;
HORWICH, A .
ANNALS OF ONCOLOGY, 1992, 3 (04) :291-296
[10]   A COMPARISON BETWEEN ESTIMATES OF GFR USING [TC-99M] DTPA CLEARANCE AND THE APPROXIMATION OF COCKCROFT AND GAULT [J].
COCHRAN, M ;
STJOHN, A .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1993, 23 (05) :494-497